// App-Quantinova.ai

: Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Researchers

Presenter

  • Michael P. Chu

Principal Investigators

  • Zack M. Breckenridge

  • Andrew Daly

  • Mona Shafey

  • Victor A. Lewis

  • Sunil J. Desai

  • Peng Wang

  • Joseph Brandwein

  • Peter Duggan

  • Beverly Wilson

  • Bindu Thapa

  • Carina Debes-Marun

  • Irwindeep Sandhu

Medical Centers

  • Department of Medicine, University of Alberta, Edmonton, Canada

  • University of Alberta/Stollery Children's Hospital, Edmonton, Canada

  • Department of Oncology, Cross Cancer Institute, Edmonton, Canada

  • Department of Pediatric Hematology-Oncology, University of Alberta/Stollery Children's Hospital, Edmonton, Canada

  • Tom Baker Cancer Center, Calgary, CAN

  • Cross Cancer Institute, Edmonton, Canada

  • Alberta Children's Hospital, University of Calgary, Calgary, Canada

  • Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada

  • Cross Cancer Institute, University of Alberta, Edmonton, Canada

  • Tom Baker Cancer Centre, University of Calgary, Calgary, Canada

  • University of Alberta, Edmonton, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved